ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.8352G>T (p.Arg2784=) (rs747664806)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000495423 SCV000578674 likely benign Breast-ovarian cancer, familial 2 2017-06-29 reviewed by expert panel curation Synonymous substitution variant, with low bioinformatic likelihood to result in a splicing aberration (Splicing prior probability 0.02; http://priors.hci.utah.edu/PRIORS/).
Ambry Genetics RCV000217568 SCV000274827 likely benign Hereditary cancer-predisposing syndrome 2015-03-24 criteria provided, single submitter clinical testing
Invitae RCV000757043 SCV000560373 likely benign not provided 2018-12-05 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000506394 SCV000600797 likely benign not specified 2017-03-31 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000757043 SCV000885107 likely benign not provided 2017-07-06 criteria provided, single submitter clinical testing
Color RCV000217568 SCV000911618 likely benign Hereditary cancer-predisposing syndrome 2018-03-19 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000506394 SCV000917038 likely benign not specified 2018-10-12 criteria provided, single submitter clinical testing Variant summary: BRCA2 c.8352G>T alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 5.3e-05 in 246210 control chromosomes, predominantly at a frequency of 0.00036 within the Latino subpopulation in the gnomAD database. This frequency is not significantly higher than expected for a pathogenic variant in BRCA2 causing Hereditary Breast and Ovarian Cancer (5.3e-05 vs 0.00075), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.8352G>T in individuals affected with Hereditary Breast and Ovarian Cancer and no experimental evidence demonstrating its impact on protein function have been reported. Co-occurrences with other likely pathogenic variant(s) have been reported (PALB2 c.8352G>T, p.Ser779X) in our internal database, providing supporting evidence for a benign role. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as likely benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.